deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 17-arm NCT03009058

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (MODULATE)

A Novel Phase I/IIa Open Label Study of IMM 101 in Combination With Selected Standard of Care (SOC) Regimens in Patients With Metastatic Cancer or Unresectable Cancer at Study Entry

Sponsor: Immodulon Therapeutics Ltd

Conditions Metastatic Cancer
Interventions Anti-PD1 Capecitabine Cyclophosphamide Fluorouracil Folinic Acid Gemcitabine IMM-101 Ipilimumab Irinotecan Nab-paclitaxel Oxaliplatin cetuximab
Updated 10 times since 2017 Last updated: Oct 9, 2024 Started: May 31, 2017 Primary completion: Aug 30, 2017 Completion: Aug 30, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Commercial reasons

Other terminated trials from Immodulon Therapeutics Ltd

More terminations from Immodulon Therapeutics Ltd

A PHASE1/PHASE2 clinical study on Metastatic Cancer, this trial is terminated or withdrawn. The trial is conducted by Immodulon Therapeutics Ltd and has accumulated 10 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotNot Yet Recruiting~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshotNot Yet Recruiting~Jun 2017 – ~Oct 2017 · 4 months · monthly snapshotActive Not Recruiting~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshotTerminated~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshotTerminated~Sep 2018 – ~Jan 2021 · 28 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshotTerminated~Dec 2024 – present · 21 months · monthly snapshotTerminated

Change History

10 versions recorded

  1. Dec 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Sep 2024 — Dec 2024 [monthly]

    Terminated PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  5. Sep 2018 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 5 earlier versions

  1. Jun 2018 — Sep 2018 [monthly]

    Terminated PHASE1_PHASE2

  2. Oct 2017 — Jun 2018 [monthly]

    Terminated PHASE1_PHASE2

    Status: Active Not Recruiting → Terminated

  3. Jun 2017 — Oct 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Active Not Recruiting

  4. Feb 2017 — Jun 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  5. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Immodulon Therapeutics Ltd
Data source: Immodulon Therapeutics Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations